

Special Issue

Gut Microbiome and Metabolome Studies in Animal Models: Clinical, Translational, and Basic Research Applications

Message from the Guest Editors

This Special Issue welcomes the submission of novel research papers with an emphasis on gut microbiome and metabolome studies in animal models. Topics that will be covered include (but are not limited to) basic, pre-clinical, and clinical research studies using animal models in the following aims: I. To understand the role(s) of the gut microbiome and metabolome in the prevention and treatment of infectious and/or chronic diseases.

ii. To assess the utility and feasibility of gut microbiome and metabolome endpoints, including biomarkers, in clinical veterinary diagnostics. iii. To evaluate novel therapeutics in animals that work via modulation of the gut microbiome and metabolome, including biologic therapeutics (e.g., probiotics, prebiotics, synbiotics, bacteriophages, etc.). Neither in vitro nor ex vivo models will be considered in this Special Issue. Additionally, studies that only present metabolomic data without concurrent microbiome analysis will not be considered.

Guest Editors


Dr. Nora Jean Nealon

Dr. Nina Kristen E. Randolph

Prof. Dr. Chi Chen

Deadline for manuscript submissions

closed (31 January 2023)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/132091

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).